RPRX
Royalty Pharma plc [RPRX] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RPRX Stock Summary
Top 10 Correlated ETFs
RPRX
Top 10 Correlated Stocks
RPRX
In the News
RPRX Financial details
Company Rating
Strong Buy
Market Cap
12.61B
Income
1.13B
Revenue
2.35B
Book val./share
14.61
Cash/share
1.11
Dividend
0.8
Dividend %
2.82%
Employees
75
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
418.94
Forward P/E
-
PEG
1.68
P/S
7.33
P/B
2.07
P/C
25.16
P/FCF
6.12
Quick Ratio
13.46
Current Ratio
13.51
Debt / Equity
0.94
LT Debt / Equity
0.61
-
-
EPS (TTM)
2.54
EPS next Y
-
EPS next Q
-
EPS this Y
2497.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-16.93%
Revenue last 5Y
5.35%
Revenue Q/Q
11.13%
EPS Q/Q
593.75%
-
-
-
-
SMA20
-6.67%
SMA50
-3.45%
SMA100
3.7%
Inst Own
53.85%
Inst Trans
0.77%
ROA
-
ROE
1%
ROC
0.06%
Gross Margin
100%
Oper. Margin
42%
Profit Margin
1%
Payout
1165%
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
25.92-36.67
52W High
-22.42%
52W Low
+11.72%
RSI
37
Rel Volume
0.38
Avg Volume
2.71M
Volume
1.03M
Perf Week
-3.86%
Perf Month
-8.03%
Perf Quarter
6.56%
Perf Half Y
-1.93%
-
-
-
-
Beta
0.446
-
-
Volatility
0.27%, 0.96%
Prev Close
0.14%
Price
27.93
Change
1.42%
RPRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 4.96 | 5.65 | 5.52 | 5.11 | 5.26 | |
| Net income per share | 6.42 | 1.48 | 1.15 | 0.1 | 2.54 | |
| Operating cash flow per share | 4.56 | 5.42 | 4.86 | 4.9 | 6.77 | |
| Free cash flow per share | -0.15 | 11.27 | 4.87 | 9.56 | 2.05 | |
| Cash per share | 2.17 | 5.31 | 6.76 | 5.54 | 1.11 | |
| Book value per share | 16.69 | 26.36 | 13.93 | 12.85 | 14.58 | |
| Tangible book value per share | 16.64 | 39.8 | 24.69 | 21.72 | 22.53 | |
| Share holders equity per share | 16.69 | 26.36 | 13.93 | 12.85 | 14.58 | |
| Interest debt per share | 17.78 | 15.91 | 17.51 | 16.68 | 14.13 | |
| Market cap | 16.28B | 18.79B | 16.53B | 17.31B | 12.57B | |
| Enterprise value | 22.24B | 23.6B | 22.08B | 22.71B | 18.23B | |
| P/E ratio | 6.93 | 33.86 | 34.53 | 404.1 | 11.08 | |
| Price to sales ratio | 8.97 | 8.86 | 7.22 | 7.74 | 5.34 | |
| POCF ratio | 9.77 | 9.24 | 8.19 | 8.07 | 4.15 | |
| PFCF ratio | -301.24 | 4.44 | 8.19 | 4.14 | 13.72 | |
| P/B Ratio | 2.67 | 1.9 | 2.86 | 3.08 | 1.93 | |
| PTB ratio | 2.67 | 1.9 | 2.86 | 3.08 | 1.93 | |
| EV to sales | 12.26 | 11.12 | 9.65 | 10.15 | 7.74 | |
| Enterprise value over EBITDA | 8.43 | 12.54 | 14.9 | 23.1 | 12.22 | |
| EV to operating cash flow | 13.34 | 11.6 | 10.95 | 10.59 | 6.01 | |
| EV to free cash flow | -411.4 | 5.58 | 10.94 | 5.43 | 19.9 | |
| Earnings yield | 0.14 | 0.03 | 0.03 | 0 | 0.09 | |
| Free cash flow yield | 0 | 0.23 | 0.12 | 0.24 | 0.07 | |
| Debt to equity | 1.02 | 0.59 | 1.23 | 1.26 | 0.94 | |
| Debt to assets | 0.5 | 0.28 | 0.41 | 0.42 | 0.37 | |
| Net debt to EBITDA | 2.26 | 2.55 | 3.75 | 5.5 | 3.79 | |
| Current ratio | 2.5 | 8.76 | 16.81 | 2.19 | 7.9 | |
| Interest coverage | 9.77 | 10.16 | 8.61 | 5.2 | 7.97 | |
| Income quality | 0.68 | 1.2 | 1.63 | 9.32 | 2.67 | |
| Dividend Yield | 0.05 | 0.02 | 0.02 | 0.02 | 0.03 | |
| Payout ratio | 0.31 | 0.72 | 0.6 | 7.78 | 0.32 | |
| Sales general and administrative to revenue | 0.06 | 0.09 | 0.08 | 0.1 | 0.11 | |
| Research and developement to revenue | 0.05 | 0.01 | 0.09 | 0.08 | 0.02 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -1.03 | 1.08 | 0 | 0.95 | -0.7 | |
| Capex to revenue | -0.95 | 1.04 | 0 | 0.91 | -0.9 | |
| Capex to depreciation | -71.95 | 95.28 | 0.02 | 359.99 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 49.09 | 29.61 | 19.02 | 5.32 | 28.84 | |
| ROIC | 0.18 | 0.03 | 0.04 | 0.01 | 0.08 | |
| Return on tangible assets | 0.19 | 0.03 | 0.03 | 0 | 0.07 | |
| Graham Net | -14.99 | -10.05 | -10.64 | -11.03 | -11.66 | |
| Working capital | 498.66M | 2.39B | 2.71B | 1.39B | 1.11B | |
| Tangible asset value | 6.09B | 14.94B | 10.24B | 9.51B | 10.08B | |
| Net current asset value | -5.48B | -3.43B | -4.39B | -4.73B | -5.02B | |
| Invested capital | 1.02 | 0.59 | 1.23 | 1.26 | 0.94 | |
| Average receivables | 118.7M | 38.97M | 53.74M | 52.45M | 405.84M | |
| Average payables | 7.83M | 10.98M | 8.2M | 6.76M | 11.54M | |
| Average inventory | 9.6M | 328.57M | 328.57M | 1 | 0.5 | |
| Days sales outstanding | 7.8 | 6.74 | 10.89 | 5.97 | 120.15 | |
| Days payables outstanding | 4 | 44.64 | 89.2 | 508.94 | 0 | |
| Days of inventory on hand | 0 | 2.72K | 0 | 0 | 0 | |
| Receivables turnover | 46.8 | 54.18 | 33.52 | 61.13 | 3.04 | |
| Payables turnover | 91.2 | 8.18 | 4.09 | 0.72 | 0 | |
| Inventory turnover | 0 | 0.13 | 23M | 5.67M | 0 | |
| ROE | 0.38 | 0.06 | 0.08 | 0.01 | 0.17 | |
| Capex per share | -4.7 | 5.85 | 0 | 4.66 | -4.73 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 1.28 | 1.53 | 1.19 | 1.2 | 1.33 | |
| Net income per share | -1.38 | 0.76 | 0.51 | 0.16 | 1.11 | |
| Operating cash flow per share | 1.29 | 2.32 | 1.35 | 1.28 | 1.74 | |
| Free cash flow per share | 0.67 | 0.97 | 1.22 | 0.27 | -0.5 | |
| Cash per share | 5.48 | 5.81 | 6.46 | 3.76 | 1.11 | |
| Book value per share | 12.7 | 13.36 | 13.95 | 13.69 | 14.61 | |
| Tangible book value per share | 21.46 | 22.01 | 21.75 | 21.34 | 22.58 | |
| Share holders equity per share | 12.7 | 13.36 | 13.95 | 13.69 | 14.61 | |
| Interest debt per share | 16.16 | 16.09 | 15.93 | 13.77 | 13.84 | |
| Market cap | 17.51B | 16.06B | 13.85B | 12.17B | 12.54B | |
| Enterprise value | 22.92B | 21.2B | 18.8B | 17.37B | 18.2B | |
| P/E ratio | -7.18 | 11.78 | 15.21 | 42.19 | 6.34 | |
| Price to sales ratio | 30.96 | 23.47 | 25.73 | 22.69 | 21.05 | |
| POCF ratio | 30.73 | 15.53 | 22.78 | 21.22 | 16.14 | |
| PFCF ratio | 58.68 | 37.15 | 25.29 | 99.44 | -55.76 | |
| P/B Ratio | 3.11 | 2.7 | 2.2 | 1.98 | 1.92 | |
| PTB ratio | 3.11 | 2.7 | 2.2 | 1.98 | 1.92 | |
| EV to sales | 40.51 | 31 | 34.93 | 32.38 | 30.54 | |
| Enterprise value over EBITDA | 135.62 | 40.19 | 68.41 | 103.4 | 29.69 | |
| EV to operating cash flow | 40.21 | 20.51 | 30.93 | 30.28 | 23.42 | |
| EV to free cash flow | 76.79 | 49.06 | 34.34 | 141.89 | -80.92 | |
| Earnings yield | -0.03 | 0.02 | 0.02 | 0.01 | 0.04 | |
| Free cash flow yield | 0.02 | 0.03 | 0.04 | 0.01 | -0.02 | |
| Debt to equity | 1.26 | 1.2 | 1.13 | 1 | 0.94 | |
| Debt to assets | 0.42 | 0.42 | 0.42 | 0.39 | 0.37 | |
| Net debt to EBITDA | 31.98 | 9.76 | 18.02 | 30.93 | 9.23 | |
| Current ratio | 2.19 | 2.36 | 2.52 | 13.51 | 7.9 | |
| Interest coverage | 2.03 | 10.2 | 5.3 | 3.29 | 13.04 | |
| Income quality | -0.93 | 2.03 | 1.73 | 4.7 | 1.57 | |
| Dividend Yield | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Payout ratio | -0.14 | 0.26 | 0.4 | 1.24 | 0.18 | |
| Sales general and administrative to revenue | 0.13 | 0.13 | 0.09 | 0.11 | 0.1 | |
| Research and developement to revenue | 0.09 | 0 | 0 | 0.09 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | -0.48 | -0.58 | -0.1 | -0.79 | -1.29 | |
| Capex to revenue | -0.48 | -0.88 | -0.11 | -0.84 | -1.68 | |
| Capex to depreciation | 47.88 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 19.84 | 15.16 | 12.59 | 7.04 | 19.08 | |
| ROIC | 0.01 | 0.02 | 0.01 | 0.01 | 0.03 | |
| Return on tangible assets | -0.04 | 0.02 | 0.01 | 0 | 0.03 | |
| Graham Net | -10.91 | -10.4 | -9.71 | -10.16 | -11.69 | |
| Working capital | 1.39B | 1.51B | 1.78B | 1.6B | 1.11B | |
| Tangible asset value | 9.51B | 9.81B | 9.8B | 9.57B | 10.08B | |
| Net current asset value | -4.73B | -4.62B | -4.35B | -4.54B | -5.02B | |
| Invested capital | 1.26 | 1.2 | 1.13 | 1 | 0.94 | |
| Average receivables | 35.72M | 37.52M | 36.83M | 36.57M | 406.5M | |
| Average payables | 12.01M | 7.28M | 6.23M | 9.72M | 14.4M | |
| Average inventory | 1 | 1 | 1 | 0.5 | 0 | |
| Days sales outstanding | 5.82 | 5.06 | 5.89 | 6.36 | 117.04 | |
| Days payables outstanding | 125.49 | 5.04 | 2.17 | 4.43 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 15.46 | 17.79 | 15.28 | 14.15 | 0.77 | |
| Payables turnover | 0.72 | 17.85 | 41.53 | 20.34 | 0 | |
| Inventory turnover | 5.67M | 118.8M | 241.23M | 0 | 0 | |
| ROE | -0.11 | 0.06 | 0.04 | 0.01 | 0.08 | |
| Capex per share | -0.61 | -1.35 | -0.13 | -1.01 | -2.24 |
RPRX Frequently Asked Questions
What is Royalty Pharma plc stock symbol ?
Royalty Pharma plc is a US stock , located in New york of Ny and trading under the symbol RPRX
What is Royalty Pharma plc stock quote today ?
Royalty Pharma plc stock price is $27.93 today.
Is Royalty Pharma plc stock public?
Yes, Royalty Pharma plc is a publicly traded company.
Company Profile
- Volume Average 2.71M
- Market Capitalization 12.61B
- Employee 75
- CEO Mr. Pablo Gerardo Legorreta
- Headquarters New York,NY,US
- IPO Date 2020-06-16
-
Website
https://www.royaltypharma.com 
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio consists of royalties on approximately 35 marketed therapies and 10 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neurology, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.
